Search

The latest research news from Retina UK.

• News
• Retinitis pigmentosa

Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.

• News
• Stargardt disease

Inside: Our intrepid Sahara Trek #TeamRetinaUK tell us about their incredible experience. 2026 is now fully underway and we are excited to tell you about our plans. Could you take part in a challenge event or volunteer to do a bucket collection in London for Retina UK?

• Look Forward
• Audio
• Written

It’s time to reflect, celebrate and look to the future... and you’re invited. Join us for an unforgettable evening as we celebrate the culmination of our 50th anniversary year.

• Fundraising Events
• London

A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.

• News
• Retinitis pigmentosa

This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.

• Look Forward
• Audio
• Written

Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.

• Look Forward
• Audio
• Written

Sam joins Retina UK, bringing a blend of scientific expertise, strategic leadership, and communication experience gained from over a decade working at Cancer Research UK.

• Trustee
• Written

Autoimmune diseases are quite distinct from inherited retinal dystrophies.

TPT and Sight Loss Councils: Cut it back campaign

• News